MedTrace Logo

Prognostic Models for HCC Based on Tumor Micronecrosis

NCT05837065 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 765

Last updated 2023-05-01

No results posted yet for this study

Summary

The heterogeneity of hepatocellular carcinoma (HCC) leads to the unsatisfying predicting performance of current staging systems. HCC patients with pathological tumor micronecrosis have immunosuppressive microenvironment. We aimed to develop novel prognostic models by integrating micronecrosis to more precisely predict the survival of HCC patients after hepatectomy.

Conditions

Interventions

OTHER

observing whether HCC patients having tumor micronecrosis

whether HCC patients having tumor micronecrosis or not

Sponsors & Collaborators

  • Zhejiang University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-15
Primary Completion
2023-03-30
Completion
2023-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05837065 on ClinicalTrials.gov